

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (2/98)
Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(h))

Attorney Docket No.

First Named Inventor or Application Identifier

William R. Camm

Title

**FORMULATIONS AND METHODS FOR
ADMINISTRATION OF PHARMACOLOGICALLY
BIOLOGICALLY ACTIVE COMPOUNDS**

Express Mail Label No.

EJ379806995US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

Assistant Commissioner for Patents
ADDRESS TO: Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (Form PTO-1082)
(Submit an original and a duplicate for fee processing)

2. ☒ Specification [Total Pages 25]
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description

- Claims

- Abstract of the Disclosure

3. ☐ Drawing(s) (35 USC 113) [Total Sheets]

4. Oath or Declaration [Total Pages 25]

a. ☐ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named
in the prior application, see 37 CFR 1.63(d)(2) and
1.33(b).

5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy
of the oath or declaration is supplied under Box 4b, is considered
as being part of the disclosure of the accompanying application
and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☐ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above
copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))

9. ☐ 37 CFR 3.73(b) Statement ☐ Power of
(when there is an assignee) Attorney

10. ☐ English Translation Document (if applicable)

11. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations

12. ☐ Preliminary Amendment

13. ☒ Return Receipt Postcard (MPEP 503)
(should be specifically itemized)

14. ☐ *Small Entity ☐ Statement filed in
Statement(s) prior application,
Status still proper
and desired

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Other:

*NOTE FOR ITEMS 1 & 14 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY
FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF
ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No: /

Prior Application Information: Examiner:


Group/Art Unit:

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 22930

or ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME	Mary S. Consalvi HOWREY & SIMON				
ADDRESS	Box No. 34 1299 Pennsylvania Avenue, N.W.				
CITY	Washington	STATE	DC	ZIP CODE	20004-2402
COUNTRY	US	TELEPHONE	202-783-0800	FAX	202-383-7195
Name (Print/Type)	Robert C. Laurensen		Registration No. (Attorney/Agent)	34,206	
Signature			Date	January 14, 2000	

EXPRESS MAIL NO. EJ379806981US

FORM PTO-1082

HOWREY & SIMON
Box No. 34
1299 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2402
(650) 463-8100

Attorney Docket No.

Box Patent Application

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of **William R. Campbell and Barry A. Omilinsky** for
FORMULATIONS AND METHODS FOR ADMINISTRATION OF PHARMACOLOGICALLY OR BIOLOGICALLY ACTIVE COMPOUNDS

Also, enclosed are:

1. Cover Sheet of Application
2. Return postcard.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR	NO. FILED	NO. EXTRA
BASIC FEE	\$690.00	
TOTAL CLAIMS	51 -20 =	31
INDEP. CLAIMS	8 -3 =	5*
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		


*If the difference in Col. 1 is less than zero, enter "0" in Col. 2

SMALL ENTITY	
RATE	FEE
	\$
x 9 =	0.00
x 39 =	0.00
+ 130 =	0.00
TOTAL	\$

OTHER THAN A SMALL ENTITY	
RATE	FEE
	\$ 690.00
31 x 18 =	\$ 558.00
5 x 78 =	\$ 390.00
+ 260 =	
TOTAL	1,638.00

This application is being filed under 37 C.F.R. §1.53(b)(1) without declaration and filing fee. Also, this application is or claims priority to .

Date January 14, 2000


Robert C. Laurenson (Reg No. 34,206)

FORMULATIONS AND METHODS FOR ADMINISTRATION OF PHARMACOLOGICALLY OR BIOLOGICALLY ACTIVE COMPOUNDS

FIELD OF THE INVENTION

The present invention is directed to formulations and methods for administering pharmacologically or biologically active compounds. In one embodiment, pharmacologically active compounds may be administered to vertebrates by diluting the formulation in the drinking water of the vertebrate. In a preferred embodiment the formulations may contain ivermectin or another parasiticide, and may be diluted in the drinking water of poultry for the treatment of a parasitic infection. The formulations and methods are useful for treating roundworms, cecal worms, lice, ticks, capillarial worms, and mite infections in poultry or other vertebrates.

In another embodiment, the pharmacologically active or biologically active compound may be a compound of agricultural interest which is administered to plants or soil surfaces by diluting the formulation in water and topically applying the diluted formulation to the plant or soil surface. In various embodiments the formulations may also be topically applied to animals.

BACKGROUND

Parasitic infections are common problems in a variety of vertebrates, including cattle, horses, swine, sheep, goats, and fowl. Various parasitic infections are also problematic in companion animals such as dogs and cats.

Chickens and other fowl are known to suffer from a variety of parasitic infections. Roundworms, cecal worms, capillarial worms, lice, ticks, and mites are among the common

parasites which may be associated with fowl and exact a substantial economic cost from the producers of fowl each year as well as raise health issues regarding the safety of the food supply.

Common methods of eliminating these parasites from fowl include the administration of piperazine to the drinking water or feed of animals. This method has had limited success due to the limited effectiveness of piperazine against these parasites. Treatment with tramisol has had somewhat better success but its use is limited by its very high cost. Therefore, animal caretakers are still in need of a cost-effective, efficacious method of eliminating these parasites.

Various useful pesticides exist which are either immiscible or unstable in aqueous solutions, making it impossible or impracticable to dissolve these compounds in water for a spray-on application to crops or animals. Thus, the agriculture industry has been unable to utilize these pesticides with the ease of application and low cost which could be associated with the compounds if they could be simply dissolved in water and sprayed onto the plants, animals, ground surfaces to be treated, or applied directly to the insects to be treated.

SUMMARY OF THE INVENTION

The present invention provides non-aqueous compositions which comprise a pharmacologically or biologically active compound, an emulsifier, a polyol, and benzyl alcohol. The compositions are useful for administering the pharmacologically or biologically active compounds which they contain to animals, plants, or ground surfaces. In preferred embodiments, the pharmacologically or biologically active compounds may be water-insoluble or water-labile. The present invention provides methods and compositions in which these compounds can be solubilized and conveniently transported to a site of application in a non-aqueous form, and then diluted in an aqueous solution. In a particularly preferred embodiment,

ound is ivermectin and is administered in the drinking water of poultry. The
tions of the present invention may also contain one or more pharmacologically or
ally active compounds.

The present invention also provides methods of administering the compounds. In the
ferred embodiment, the compounds may be administered in the drinking water of
to be treated with the pharmacologically or biologically active compound. In other
nents, the compositions may be topically applied to the animals or plants to be treated, or
onto plants, animals, or a ground surface to be treated with the active compounds.

n. The
lsifier,
lution

ention,
plant or
ay be

DETAILED DESCRIPTION OF THE INVENTION

By “parasiticide” is meant any ectoparasiticide, acaricide, miticide, pediculicide, and
anthic.

By “anti-parasitic agent” is meant a miticide or an antihelminthic agent, including but
ed to ivermectin.

By “clinically effective amount” is that amount sufficient to have a therapeutically
effect on the treated organism. A therapeutically relevant effect relieves to some extent
more symptoms in the treated vertebrate.

By “emulsifier” is meant a surface active agent promoting the formation and stabilization
ulsion.

By “surfactant” is meant a surface active substance, or a substance which lowers the
at the surface of contact between phases.

The present invention relates to formulations and methods for administering
ologically or biologically active compounds to vertebrates, plants, insects, and ground

ie
1 water
to
und.
a
ation
ultry.
nd
of
a
ther
soil

supporting the plants. In other embodiments, a compound of interest may be diluted into an aqueous solution and applied to a surface to be treated with the compound, such as a surface supporting plants, for the purpose of destroying foliage.

The present invention offers particular advantages in the administration of compounds which are water insoluble and/or water labile. It is found that water labile compounds are able to retain their stability in aqueous solutions for at least 10 days when administered in formulations of the present invention. It is also found that water insoluble compounds may be effectively diluted and administered in aqueous solutions, including drinking water, when administered as a formulation of the present invention. Water insoluble compounds are found to not form aggregates or clumps when formulated according to the present invention, and to disperse relatively uniformly in aqueous solutions to provide a steady dose of the pharmacologically or biologically active compound to the treated vertebrate drinking the water or a uniform dose to the plants, insects, or ground surface being treated with the formulation. The formulation may be diluted in any aqueous solution. In a preferred embodiment, the formulation is diluted and administered in the drinking water of a vertebrate.

Thus, the present invention makes available compositions and methods for conveniently and efficiently administering a wide range of pharmacologically or biologically active compounds to a wide range of vertebrates in a convenient manner. Many of these compounds could not formerly be easily administered in water due to the water-insoluble and/or water labile characteristics of the compound. For example, water insoluble and/or water labile compounds to which the present invention may be applied may include, but are not limited to: ivermectin, doramectin, avermectin, abamectin, milbemycin, amprolium, bacitracin, chlortetracycline, erythromycin, lincomycin/spectinomycin, neomycin, oxytetracycline, piperazine, sarafloxacin,

spectinomycin, sulfachloro-pyrazine, sulfadimethoxine, sulfamethazine, sulfaquinoxaline, tetracycline, tylosin, milbemycin, and spinosad. These compounds, which are often difficult to administer in drinking water or other aqueous solutions due to their lack of solubility or their instability in water, are provided as examples and are not intended to be limiting. The named compounds are meant to encompass their salt forms as well.

As noted above, ivermectin could not formerly be administered to birds or animals in drinking water because of the water-labile nature of ivermectin, which tends to quickly lose its pharmacological efficacy in aqueous solutions. Applying the principles of the present invention, we have achieved the complete elimination of roundworms and cecal worms from turkeys in three days by administering ivermectin in a formulation of present invention. The ivermectin formulation is conveniently administered by dilution of the formulation in the drinking water of the birds and requires no further effort since the compound's stability and potency in water is maintained for at least 10 days. The present invention may also be useful for treating a variety of other parasitic infections in poultry or other animals including, but not limited to, capillarial worms, mites, ticks, and lice.

Various pesticide compounds may be more conveniently and economically administered as a formulation of the present invention. For example, the phenyl pyrazole insecticides, pyrethroid insecticides and non-ester pyrethroid insecticides may all be administered according to the present invention. Thus, these compounds may be formulated according to the present invention and sprayed or otherwise applied to the plants, animals, or ground surfaces to be treated, or applied directly to the insects to be eliminated.

The person of ordinary skill in the art will identify other compounds, both existing and yet to be discovered, which may be utilized in the present invention and which are meant to be

encompassed within the scope of the present invention. Thus, the concepts of the present invention are not limited to a particular group of compounds or for particular purposes. Rather, the present invention offers a formulations and methods for administering or delivering a compound of interest under a variety of circumstances.

The present formulations and methods are particularly advantageous in that a compound of interest may be formulated and transported as a non-aqueous formulation to a site of administration, and diluted in an aqueous solution at the site of administration to the animals, plants, insects, or surface to be treated. The formulations are especially advantageous when the compound of interest is water insoluble and/or water labile since the formulations of the present invention make it possible to administer these compounds in an aqueous solution in a convenient and cost-efficient manner.

The Formula

The formulations of the present invention are exemplified herein as the principles may be applied to ivermectin for administration to the drinking water of turkeys and other fowl. However, these examples are not intended to be limiting and the person of ordinary skill in the art will realize that these methods may be applied to administer a variety of pharmacologically and biologically active compounds such as those listed above and others to treat various illnesses and infections in a variety of animals, including but not limited to cattle, horses, swine, sheep, goats, and fowl.

The formulation of the present invention may comprise a clinically effective amount of a pharmacologically or biologically active compound, an emulsifier, a polyol, and benzyl alcohol.

In a preferred embodiment, the formulation comprises (w/w):

2.02% ivermectin;

25.0% polysorbate 80 (e.g., Tween 80™, Uniqema, Wilmington, Delaware)

57.98% propylene glycol;

15% benzyl alcohol.

The formula of the present invention is prepared as follows: A kettle is charged with the benzyl alcohol and agitation is begun. The ivermectin or other compound of interest is added and the formula agitated until it dissolves. The vessel may be warmed to 40°C in order to speed dissolution. The propylene glycol and polysorbate 80 (Tween 80™ or its equivalent) are added. The formula is blended for 15 minutes or until uniform. The sample may then be aliquoted, assayed, and packaged. This procedure results in a stable, non-aqueous formulation that is approximately 2.0% ivermectin.

The person of ordinary skill in the art will realize that substitutions may be made for one or more of the components of the formulation. For example, other polyols may be substituted for propylene glycol. Also, n-methyl-pyrrolidone (NMP) may be substituted for the polyol. Similarly, other surfactants may be substituted for the polysorbate 80 (Tween 80™), such as polysorbate 85, polysorbate 20, organosilicones, or polysiloxanes. These substitutions will preserve the chemical effect of the compound being substituted and are contemplated as being within the scope of the present invention. Without wanting to be bound by any particular theory, it is believed that the benzyl alcohol may be showing the surprising effect of solubilizing the polysorbate 80 in the propylene glycol. It is also believed that polysorbate 80 may serve as a

surface active agent which acts to partition the oil phase and water-soluble phases. It is believed that the polysorbate 80 may also facilitate the dissolution of the product in the water soluble phase upon dilution at the site of administration. It is also believed that the propylene glycol, or any polyol or n-methyl pyrrolidone, or any monohydric alcohol **[DOES MONOHYDRIC ALCOHOL BELONG HERE?]**, may serve to solubilize the ivermectin and confer water solubility to the total formulation. Thus, the particular combination of components of the present invention combine to confer water solubility and water stability on water-insoluble and water-labile compounds such as ivermectin and other water insoluble or water-labile compounds.

Surfactants or surface active agents which are particularly suited for use in the compositions of the present invention are ionic or non-ionic surface active compounds generally well known in the art. Such agents generally have an oleophilic portion of the molecule, usually of hydrocarbon nature, and another polar portion of the molecule, which may be provided by various functional groups such as hydroxyl, sulfate, carboxyl, carbonyl, amino, nitro, amide, ether, sulfonate, phosphate, phosphite, etc. Examples of suitable classes of surface active agents which can be employed are alkali metal salts of fatty acids, alkali metal salts of sulfonated fatty acids, fatty acid glycerides, sulfonated or sulfated fatty acid esters or amides, alkali metal sulfates, alkali metal alkyl sulfonates, alkali metal aryl sulfonates, alkali metal alkyl lauryl sulfonates, quaternary ammonium halides, alkali metal salts of alkylated naphthalene, sulfonic acid, polyethylene sorbitol esters of fatty acids, fatty acid amides of alkanol amines, condensation products of ethylene oxide and polyalkylene glycols, sorbitan esters, alkyl substituted phosphoric acids, alkali metal salts of alkyl phenol sulfonates, polyalkyleneoxide polysiloxanes, etc.

Preparation for Administration

The formula of the present invention is diluted before administration to the animals, plants, insects, or ground surface to be treated as follows. In this example, the formula is prepared for administration of ivermectin in the drinking water of fowl for the treatment of parasites, but the person of ordinary skill in the art will realize that the formula may be diluted for the administration of many pharmacologically active compounds to any type of animal, plant, insect, or surface.

Example 1

The 2% ivermectin solution is diluted 20-fold to 0.1% in water. From the 0.1%, 3.4 ml is dissolved in 5 liters (QS) of water. The dose to be administered in order to obtain effective treatment of various parasites depends on the size of the fowl to be treated (i.e., their drinking capacity). A 4.5 kg turkey will typically drink 600-1000 ml of water every 24 hours. This corresponds to a dose of 100-150 $\mu\text{gm/kg/day}$. It is found that a dose of 200 mg ivermectin/kg body weight/day is effective to completely eliminate roundworms (*Ascaridia*) and cecal worms (*Heterakis*) in turkeys in three days. The effective dose to administer to any other type of animal to treat a particular type of parasite can be easily determined by simply varying the dosage until arriving at an effective dose.

A non-aqueous, stable formulation of ivermectin was prepared and diluted into the drinking water of market male turkeys as described above. The turkeys had an average weight of 4.5 kg and had a history of roundworm infestation (*Ascaridias*). The birds were treated at levels of 10, 50, 100, 200, 250, 500, 1200, and 1400 mg/kg of body weight/day. The water consumption by the turkeys was normal and the birds did not refuse drinking water due to

treatment at any level. The formulation was effective at completely eliminating any visible signs of roundworm infestation at levels down to 200 mg/kg body weight/day in three days.

The person of ordinary skill will realize that the present invention finds applicability for the administration of many pharmacologically and biologically active compounds. For example, the present invention may be applied to pesticides, nutrients or other compounds (some of which are listed below) for administration in drinking water, or for topical administration to animals, plants, or ground or other surfaces. The present invention is therefore applicable to treating any of the wide variety of diseases which may be treated by administration of a formulation of the present invention.

Pesticides

Many types of pesticides may be employed in the present invention, including herbicides, fungicides, growth regulators, insecticides, and acaracides. The following is a partial list of those compounds that may be utilized according to the present invention. The list is provided as representative examples and is not intended to be comprehensive and the person of ordinary skill will understand that many other compounds may also be utilized according to the present invention.

Acaracides

Clofentezine, formetanate hydrochloride, formetanate hydrochloride, hexythiazox, dicofol, fenbutatin oxide, abamectin, and milbemycin.

Fungicides

Metalaxyl, oxadixyl, Azoxystrobin, bayleton, triadimefon baytan, triadimenol, benomyl, chlorothalonil, captan, carboxin, cymoxanil, difenoconazole, mancozeb, difenoconazole, etridiazole, hymexazol, imazalil, fludioxonil, thiabendazole, thiophanate methyl, propiconazole

Growth regulators

Phenoxy Acetic Acids

Phenoxy Propionic Acids

Mecoprop

Phenoxy Butyric Acids

Benzoic Acids, such as Dicamba

Other growth regulators

Fluoroxypyr

Picloram

Triclopyr

Copyralid

Insecticides

Permethrin, Esfenvalerate, Carbaryl, Chlorpyrifos, Dimethoate, Malathion, Abamectin, Acephate, Diflubenzuron, Endosulfan, Oxydemeton methyl, Oxamyl, Methidathion, Imidacloprid, Cyromazine, Isazofos, Bendiocarb, Cyfluthrin, Diazinon, Bifenthrin, Carbofuran, Phosmet, Methoxychlor, Pirimicarb, Tebufenozide, Azadirachtin, Tefluthrin,

Herbicides

Photosynthesis inhibitors

Triazines and s-Triazines such as

Hexazinone

Metribuzin

Atrazine

Simazine

Cyanazine Prometon

Ametryn

Pigment Inhibitors, such as

Amitrole
Clomazone
Fluridone
Norflurazone

Substituted Ureas, such as

Diuron
Linuron
Tebuthiuron
Uracils, such as Bromacil
Terbacil

Other photosynthesis inhibitors, such as

Bentazon
Desmedipham
Methazole
Phenmedipham
Propanil
Pyridate

Mitotic disruptors:

Dinitroanilines, such as Oryzalin
Pendimethalin
Prodiamine
Trifluralin

Inhibitors of amino acid synthesis, such as

Glyphosate
Sulfonylureas, such as
Bensulfuron

Chlorimuron
Chlorsulfuron
Metsulfuron
Nicosulfuron
Primisulfuron
Sulfometuron
Thifensulfuron
Trisulfuron
Tribenuron
Imidazolinone, such as Imazamethabenz
Imazapyr
Imazaquin
Imazethapyr

Inhibitors of lipid biosynthesis, such as

Clethodim
Diclofop-methyl
Fenoxaprop-ethyl
Fluazifop-P-butyl
Haloxypop-methyl
Quizalofop
Sethoxydim

Cell wall inhibitors, such as

Dichlobenil
Isoxaben

Cell membrane disruptors:

Bipyridylium compounds, such as:
Diquat
Paraquat

Diphenylethers, such as

Acifluorfen

Fomesafen

Lactofen

Oxyfluorfen

Other herbicides

Glufosinate

Bromoxynil

Natural Insect Growth Regulators

Azadirachtin

Dihydroazadirachtin

Attractants

Plant Volatiles

Oil of Anise

Indole

Oil of Orange

Cinamaldehyde

Geraniol

Eugenol

Oil of Citronella

Repellants

Anthraquinone

Capsaicin

Linalool

Methyl Anthranilite

Cedarwood Oil

Miscellaneous Biochemicals

Canola Oil

Neem Oil

Castor Oil

Jojoba Oil

Canola Oil
Neem Oil
Castor Oil
Jojoba Oil

We claim:

1. A non-aqueous composition comprising:
an emulsifier;
a polyol;
benzyl alcohol; and
a pharmacologically or biologically active compound.
2. The composition of claim 1 provided in a form suitable for dilution in aqueous solutions.
3. The composition of claim 1 wherein the pharmacologically active compound is a parasiticide.
4. The composition of claim 3 wherein the parasiticide is selected from the group consisting of: ivermectin, doramectin, avermectin, abamectin, milbemycin, amprolium, bacitracin, chlortetracycline, erythromycin, lincomycin/spectinomycin, neomycin, oxytetracycline, piperazine, sarafloxacin, spectinomycin, sulfachloro-pyrazine, sulfadimethoxine, sulfamethazine, sulfaquinoxaline, tetracycline, and tylosin.
5. The composition of claim 4 wherein the parasiticide is selected from the group consisting of: bacitracin, chlortetracycline, erythromycin, lincomycin, oxytetracycline, piperazine, spectinomycin, and tetracycline.
6. The composition of claim 3 wherein the parasiticide is ivermectin.
7. The composition of claim 1 wherein the emulsifier is selected from the group consisting of: polysorbate 80, polysorbate 85, polysorbate 20, and polysiloxanes [organosilicones].
8. The composition of claim 7 wherein the emulsifier is polysorbate 80.
9. The composition of claim 1 wherein the polyol is propylene glycol.

10. The composition of claim 1 wherein the emulsifier is polysorbate 80 and the polyol is propylene glycol.
11. The composition of claim 10 wherein the pharmacologically active compound is ivermectin.
12. A non-aqueous composition comprising:
an emulsifier;
n-methyl pyrrolidone;
benzyl alcohol; and
a pharmacologically or biologically active compound.
13. The composition of claim 12 provided in a form suitable for dilution in aqueous solutions and wherein the pharmacologically active compound is a parasiticide.
14. The composition of claim 15 wherein the parasiticide is selected from the group consisting of: bacitracin, chlortetracycline, erythromycin, lincomycin, oxytetracycline, piperazine, spectinomycin, and tetracycline.
15. The composition of claim 13 wherein the parasiticide is ivermectin.
16. The composition of claim 18 wherein the emulsifier is polysorbate 80 and the pharmacologically active compound is ivermectin.
17. A method of administering a pharmacologically active compound to a vertebrate, comprising:
providing the pharmacologically active compound in the form of a non-aqueous formulation which further comprises
an emulsifier,
benzyl alcohol, and

a polyol;

diluting the formulation in an aqueous solution; and

administering the compound in the drinking water of the vertebrate.

18. The method of claim 17 wherein the pharmacologically active compound is water labile or water-insoluble.
19. The method of claim 17 wherein the vertebrate is a fowl.
20. The method of claim 17 wherein the vertebrate is a mammal.
21. The method of claim 20 wherein the mammal is selected from the group consisting of: bovines, equines, ovines, caprines, canines, felines, and porcines.
22. The method of claim 17 wherein the pharmacologically active compound is a parasiticide.
23. The method of claim 22 wherein the parasiticide is ivermectin.
24. The method of claim 17 wherein the pharmacologically active compound is selected from the group consisting of: ivermectin, doramectin, avermectin, abamectin, milbemycin, amprolium, bacitracin, chlortetracycline, erythromycin, lincomycin/spectinomycin, neomycin, oxytetracycline, piperazine, sarafloxacin, spectinomycin, sulfachloropyrazine, sulfadimethoxine, sulfamethazine, sulfaquinoxaline, tetracycline, and tylosin.
25. The composition of claim 24 wherein the parasiticide is selected from the group consisting of: bacitracin, chlortetracycline, erythromycin, lincomycin, oxytetracycline, piperazine, spectinomycin, and tetracycline.
26. A method of administering a pharmacologically active compound to a vertebrate, comprising:

providing the pharmacologically active compound in the form of a non-aqueous formulation comprising

an emulsifier,

benzyl alcohol,

n-methyl pyrrolidone;

diluting the formulation in an aqueous solution; and

administering the compound in the drinking water of the vertebrate.

27. The method of claim 26 wherein the pharmacologically active compound is water labile or water-insoluble.
28. The method of claim 26 wherein the vertebrate is a fowl or a mammal.
29. The method of claim 26 wherein the pharmacologically active compound is a parasiticide.
30. The method of claim 29 wherein the parasiticide is ivermectin.
31. The method of claim 26 wherein the pharmacologically active compound is selected from the group consisting of: ivermectin, doramectin, avermectin, abamectin, milbemycin, amprolium, bacitracin, chlortetracycline, erythromycin, lincomycin/spectinomycin, neomycin, oxytetracycline, piperazine, sarafloxacin, spectinomycin, sulfachloro-pyrazine, sulfadimethoxine, sulfamethazine, sulfaquinoxaline, tetracycline, and tylosin.
32. A method of administering a pharmacologically or biologically active compound to an organism comprising:

providing the biologically active compound in the form of a non-aqueous formulation further comprising an emulsifier, a polyol, and benzyl alcohol;

diluting the non-aqueous formulation in an aqueous solution;

topically applying the diluted formulation to the organism to be treated.

33. The method of claim 32 wherein the organism is a plant.
34. The method of claim 33 wherein the plant is an agricultural crop.
35. The method of claim 33 wherein the biologically active compound is a pesticide.
36. The method of claim 35 wherein the pesticide is selected from the group consisting of:
clofentezine, formetanate hydrochloride, formetanate hydrochloride, hexythiazox,
dicofol, fenbutatin oxide, abamectin, and milbemycin, metalaxyl, oxadixyl, azoxystrobin,
bayleton, triadimefon baytan, triadimenol, benomyl, chlorothalonil, captan, carboxin,
cymoxanil, difenoconazole, mancozeb, difenoconazole, etridiazole, hymexazol, imazalil,
fludioxonil, thiabendazole, thiophanate methyl, propiconazole, phenoxy acetic acids,
phenoxy propionic acids, mecoprop, phenoxy butyric acids, benzoic acids, fluoroxypry,
picloram, triclopyr, copyralid, permethrin, esfenvalerate, carbaryl, chlorpyrifos,
dimethoate, malathion, abamectin, acephate, diflubenzuron, endosulfan, oxydemeton
methyl, oxamyl, methidathion, imidacloprid, cyromazine, isazofos, bendiocarb,
cyfluthrin, diazinon, bifenthrin, carbofuran, phosmet, methoxychlor, pirimicarb,
tebufenozide, azadirachtin, tefluthrin, hexazinone, metribuzin, atrazine, simazine,
cyanazine prometon, ametryn, amitrole, clomazone, fluridone, norflurazone, diuron,
linuron, tebuthiuron, bromacil, terbacil bentazon, desmedipham, methazole,
phenmedipham, propanil, pyridate, oryzalin, pendimethalin, prodiamine, trifluralin,
glyphosate, bensulfuron, chlorimuron, chlorsulfuron, metsulfuron, nicosulfuron,
primisulfuron, sulfometuron, thifensulfuron, trisulfuron, tribenuron, imazamethabenz,
imazapyr, imazaquin, imazethapyr, clethodim, diclofop-methyl, fenoxaprop-ethyl,
fluazifop-P-butyl, haloxyfop-methyl, quizalofop, sethoxydim, dichlobenil, isoxaben,
diquat, paraquat, acifluorfen, fomesafen, lactofen, oxyfluorfen, glufosinate, bromoxynil,
azadirachtin, dihydroazadirachtin, attractants, plant volatiles, oil of anise, indole, oil of
orange, cinamaldehyde, geraniol, eugenol, oil of citronella, anthraquinone, capsaicin,
linalool, methyl anthranilite, cedarwood oil, canola oil, neem oil, castor oil, jojoba oil,
doramectin, gibberellic acid, oil of eucalyptus, linalool.

37. The method of claim 36 wherein the pesticide is abamectin, ivermectin, spinosad, milbemycin oxime, milbemectin, doramectin, permethrin, bifenthrin, azadirachtin, glyphosate, nicosulfuron, bromoxynil, indole, butyric acid, gibberellic acid, capsaicin, methyl anthranilate, neem oil, eugenol, oil of citronella, oil of eucalyptus, linalool.
38. The method of claim 32 wherein the pharmacologically active compound is topically applied by spraying onto the organism to be treated.
39. A method of administering a pharmacologically or biologically active compound to an organism comprising:

providing the biologically active compound in the form of a non-aqueous formulation further comprising an emulsifier, n-methyl pyrrolidone, and benzyl alcohol;

diluting the non-aqueous formulation in an aqueous solution;

topically applying the diluted formulation to the organism to be treated.
40. The method of claim 39 wherein the organism is an agricultural crop.
41. The method of claim 39 wherein the biologically active compound is a pesticide.
42. The method of claim 41 wherein the pesticide is selected from the group consisting of: clofentezine, formetanate hydrochloride, formetanate hydrochloride, hexythiazox, dicofol, fenbutatin oxide, abamectin, and milbemycin, metalaxyl, oxadixyl, azoxystrobin, bayleton, triadimefon baytan, triadimenol, benomyl, chlorothalonil, captan, carboxin, cymoxanil, difenoconazole, mancozeb, difenoconazole, etridiazole, hymexazol, imazalil, fludioxonil, thiabendazole, thiophanate methyl, propiconazole, phenoxy acetic acids, phenoxy propionic acids, mecoprop, phenoxy butyric acids, benzoic acids, fluoroxypr, picloram, triclopyr, copyralid, permethrin, esfenvalerate, carbaryl, chlorpyrifos, dimethoate, malathion, abamectin, acephate, diflubenzuron, endosulfan, oxydemeton methyl, oxamyl, methidathion, imidacloprid, cyromazine, isazofos, bendiocarb, cyfluthrin, diazinon, bifenthrin, carbofuran, phosmet, methoxychlor, pirimicarb, tebufenozide, azadirachtin, tefluthrin, hexazinone, metribuzin, atrazine, simazine,

cyanazine prometon, ametryn, amitrole, clomazone, fluridone, norflurazone, diuron, linuron, tebuthiuron, bromacil, terbacil bentazon, desmedipham, methazole, phenmedipham, propanil, pyridate, oryzalin, pendimethalin, prodiamine, trifluralin, glyphosate, bensulfuron, chlorimuron, chlorsulfuron, metsulfuron, nicosulfuron, primisulfuron, sulfometuron, thifensulfuron, trisulfuron, tribenuron, imazamethabenz, imazapyr, imazaquin, imazethapyr, clethodim, diclofop-methyl, fenoxaprop-ethyl, fluazifop-P-butyl, haloxyfop-methyl, quizalofop, sethoxydim, dichlobenil, isoxaben, diquat, paraquat, acifluorfen, fomesafen, lactofen, oxyfluorfen, glufosinate, bromoxynil, azadirachtin, dihydroazadirachtin, attractants, plant volatiles, oil of anise, indole, oil of orange, cinamaldehyde, geraniol, eugenol, oil of citronella, anthraquinone, capsaicin, linalool, methyl anthranilite, cedarwood oil, canola oil, neem oil, castor oil, jojoba oil, doramectin, gibberellic acid, oil of eucalyptus, linalool.


43. A method of administering a pharmacologically or biologically active compound to a surface comprising:
- providing the pharmacologically or biologically active compound in the form of a non-aqueous formulation comprising an emulsifier, a polyol or n-methyl pyrrolidone, and benzyl alcohol;
 - diluting the non-aqueous formulation in an aqueous solution;
 - topically applying the diluted formulation to the surface to be treated.
44. The method of claim 43 wherein the surface is a ground surface.
45. A non-aqueous composition comprising:
- an emulsifier;
 - a polyol;
 - a monohydric alcohol; and
 - a pharmacologically or biologically active compound.

46. The composition of claim 45 provided in a form suitable for dilution in aqueous solutions.
47. The composition of claim 45 wherein the pharmacologically active compound is a parasiticide.
48. The composition of claim 47 wherein the parasiticide is selected from the group consisting of: ivermectin, doramectin, avermectin, abamectin, milbemycin, amprolium, bacitracin, chlortetracycline, erythromycin, lincomycin/spectinomycin, neomycin, oxytetracycline, piperazine, sarafloxacin, spectinomycin, sulfachloro-pyrazine, sulfadimethoxine, sulfamethazine, sulfaquinoxaline, tetracycline, and tylosin.
49. The composition of claim 48 wherein the parasiticide is selected from the group consisting of: bacitracin, chlortetracycline, erythromycin, lincomycin, oxytetracycline, piperazine, spectinomycin, and tetracycline.
50. The composition of claim 47 wherein the parasiticide is ivermectin.
51. The composition of claim 45 wherein the emulsifier is polysorbate 80 and the polyol is propylene glycol.
- 52.

ABSTRACT

The present invention provides non-aqueous compositions which comprise a pharmacologically or biologically active compound, an emulsifier, a polyol, and benzyl alcohol. The compositions are useful for administering the pharmacologically or biologically active compounds which they contain to animals, plants, or ground surfaces. In preferred embodiments, the pharmacologically or biologically active compounds may be water-insoluble or water-labile. The compositions of the present invention allow these compounds to be solubilized and conveniently transported to a site of application in a non-aqueous form, and then diluted in an aqueous solution. In a particularly preferred embodiment, the compound is ivermectin and is administered in the drinking water of poultry. The compositions of the present invention may also contain multiple pharmacologically or biologically active compounds which are administered simultaneously. The present invention also provides methods of administering the compounds. In the most preferred embodiment, the compounds may be administered in the drinking water of animals to be treated with the pharmacologically or biologically active compound. In other embodiments, the compositions may be topically applied to the animals or plants to be treated, or sprayed onto plants, animals, or a ground surface to be treated with the active compounds.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED 1

Application deficiencies were found during scanning:

☒ Page(s) 17 of Specification were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.

PRINT OF DRAWINGS
AS ORIGINALLY FILED